Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
Massachusetts General, Harvard select Illumina HumanHap300 BeadChips for ALS research
September 20th, 2006
Illumina, Inc., (ILMN) announced that investigators at Massachusetts General Hospital (MGH) and Harvard Medical School will utilize data from Sentrix HumanHap300 BeadChips and Infinium assay reagents to perform a 2200-sample case/control whole-genome association study of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. ALS, also known as Lou Gehrig's disease, is a rapidly progressing, fatal disorder that attacks the motor neurons of the brain and spinal cord. Over one-half million patients worldwide have been diagnosed with the disease, for which there is no cure. The study will be supervised by Dr. Robert Brown of MGH and Harvard...
Source: Biotech Week (2006-09-20)
|
